Susquehanna International Group
IMNP

Susquehanna International Group’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Susquehanna International Group’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,858
Closed -$6K – 10906
2018
Q1 		$6K Buy
16,858
+2,607
+18% +$1.24K ﹤0.01% 9196
2017
Q4 		$8K Buy
+14,251
New +$13.6K ﹤0.01% 9126
2017
Q3 		– Sell
-69,805
Closed -$215K – 10122
2017
Q2 		$215K Buy
69,805
+67,339
+2,731% +$181K ﹤0.01% 8175
2017
Q1 		$7K Sell
2,466
-508
-17% -$1.83K ﹤0.01% 8793
2016
Q4 		$11K Sell
2,974
-1,367
-31% -$5.62K ﹤0.01% 9469
2016
Q3 		$24K Buy
+4,341
New +$32.1K ﹤0.01% 8241
2015
Q1 		– Sell
-1,000
Closed -$38K – 10269
2014
Q4 		$38K Hold
1,000
– – ﹤0.01% 9413
2014
Q3 		$67K Buy
+1,000
New +$71.2K ﹤0.01% 9166

Other funds holding IMNP

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's IMNP Position: Q2 2018 in Review

Susquehanna International Group sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2018, closing a stake of 16,858 shares — an estimated $6K sold.

Susquehanna International Group first reported a position in IMNP in Q3 2014 and held it in 8 quarters. The position peaked at $215K in Q2 2017. 13 funds tracked by Wall St. Rank hold IMNP as of Q2 2018.

  • Susquehanna International Group reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Susquehanna International Group sold 16,858 Immune Pharmaceuticals Inc. shares in Q2 2018, an estimated $6K.
  • Susquehanna International Group first reported a position in Immune Pharmaceuticals Inc. in Q3 2014 and held it in 8 quarters.
  • Susquehanna International Group's Immune Pharmaceuticals Inc. position peaked at $215K in Q2 2017.
  • 13 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2018.

Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.